Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Estrela Lima, Alessandra ^a,d   Araújo, Márcio S S ^b   Costa Neto, João M ^a   Teixeira Carvalho, Andréa ^b   Barrouin Melo, Stella M ^a   Cardoso, Sergio V ^c   Martins Filho, Olindo A ^b   Serakides, Rogéria ^d   Cassali, Geovanni D ^d  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOPHENOTYPING; INFLAMMATION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MIXED TUMOR; NONHUMAN; PROGNOSIS; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; ANIMAL; ANIMAL DISEASE; CARCINOMA; CD4 CD8 RATIO; DOG DISEASE; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; METASTASIS; PATHOLOGY; TIME;

ANIMALS; CARCINOMA; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOG DISEASES; DOGS; FEMALE; FLOW CYTOMETRY; IMMUNOPHENOTYPING; INFLAMMATION; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM STAGING; PROGNOSIS; TIME FACTORS;

EID: 77953005050     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-256     Document Type: Article

References (48)

1. Misdorp W. Tumors of the mammary gland. Tumors in Domestic Animals 2002, 575-606. Iowa State: University of California, Meuten DJ, 4.
2. Peleteiro MC. Tumores mamários na cadela e na gata. Revista Portuguesa de Ciências Veterinárias 1994, 89(509):10-29.
3. Cassali GD, Gobbi H, Malm C, Schmitt FC. Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: comparative features with human tumours. Cytopathology 2007, 18(3):191-6.
4. Genelhu MC, Cardoso SV, Gobbi H, Cassali GD. A comparative study between mixed-type tumors from human salivary and canine mammary glands. BMC Cancer 2007, 7:218. 10.1186/1471-2407-7-218, 2233636, 18045453.
5. Bertagnolli AC, Cassali GD, Genelhu MCLS, Costa FA, Oliveira JFC, Gonçalves PBD. Immunohistochemical expression of p63 and {Delta}Np63 in mixed tumors of canine mammary glands and its relation with p53 expression. Veterinary Pathology 2009, 46:407-415. 10.1354/vp.08-VP-0128-C-FL, 19176510.
6. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, Marconato L, Abramo F, Ciliberto G, Lahm A, Monica N, Rinaldis E. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 2009, 135(10):1-20.
7. Denardo DG, Coussens LM. Review Inflammation and breast cancer: Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research 2007, 9(4):s10.
8. Coussens LM, Werb Z. Inflammatory cells and cancer: think different!. Journal Experimental Medicine 2001, 193(6):23-26.
9. De Visser KE, Eichten A, Coussen L. Paradoxical roles of the immune during cancer development. Nature Reviews 2006, 6:24-40. 10.1038/nrc1782, 16397525.
10. Stewart THM, Heppner GH. Immunological enhancement of breast cancer. Parasitology 1997, 115:141-153.
11. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912. 10.1038/onc.2008.271, 18836471.
12. Thun MJ, Henley SJ, Gansler T. Inflammation and cancer: an epidemiological perspective. Novartis Found Symposium 2004, 256:6-21.
13. Whiteside TL. The local tumor microenvironment. General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology 2007, 145-167. Springer, Kaufmann H, Wolchok JD.
14. Marx J. Inflammation and cancer: The link grows stronger. Science 2004, 306:966-968. 10.1126/science.306.5698.966, 15528423.
15. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-44. 10.1038/nature07205, 18650914.
16. Murri AM AI, Hilmy M, Bell J, Wilson C, McNicol AM, Lannigan A, Doughty JC, McMillan DC. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. British Journal Cancer 2008, 99:1013-19.
17. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K. Lymphocytes infiltrates as a prognostic variable in female breast cancer. European Journal Cancer 1992, 28:859-864.
18. Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Annals Surgical Oncology 1996, 3(2):176-184.
19. Ben-Baruch A. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Research 2003, 31(5):31-36.
20. Rutten VP, Misdorp W, Gauthier A, Estrada M, Mialot JP, Parodi AL, Rutteman GR, Weyer K. Immunological aspects of mammary tumors in dogs and cats: a survey including own studies and pertinent literature. Veterinary Immunopathology 1990, 26(3):211-25.
21. O'Sullivan C, Lewis CE. Tumour associated leucocytes: friends or foes in breast carcinoma. Journal Pathology 1994, 172:229-235.
22. Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner. Clonal analysis and in situ characterization of lymphocytes infiltration human breast carcinomas. Cancer Immunology Immunotherapy 1986, 23:169-178.
23. Nowak M, Madej JP, Rossowska J, Madej JA. Involvement of CD8+ cells in protective mechanisms in canine mammary adenocarcinomas (short communication). Bull Veterinary Institute Pulawy 2007, 51:445-448.
24. Misdorp W, Else W, Hellm'en E, Lipscomb TP. Histological classification of the mammary tumors of the dog and the cat. Second Series. WHO International Histological Classification Tumors of Domestic Animals 1999, 2:s59. Washington, DC, AFIP.
25. Cassali GD, Serakides R, Gärtner F, Schmitt FC. Invasive micropapillary carcinoma. A case report. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 2002, 54(4):366-369.
26. Owen LN. TNM Classification of tumors in Domestic Animals. 1980, 26-32. World Health Organization, Geneva.
27. Luna LG. Manual of histologic staining methods of the Armed Forces Institute of Pathology. 1968, New York: McGraw Hill.
28. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: experience from a large study with long-term followup. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
29. Van Diest JP, Baak JPA, Matze-Cok P, Wisse-Brekelmans EC, Van Galen CM, Kurver PH, Bellot SM, Fijnheer J, Van Gorp LH, Kwee WS. Reproducibility of mitosis counting in 2469 breast cancer specimens: Results from the multicenter morphometric mammary carcinoma project. Human Pathology 1992, 23:603-607. 10.1016/0046-8177(92)90313-R, 1592381.
30. Dutra AP, Azevedo Junior GM, Schmitt FC, Cassali GD. Assessment of cell proliferation and prognostic factors in canine mammary gland tumors. Arquivo Brasileiro Medicina Veterinaria e Zootecnia 2008, 60(6):1403-1412.
31. Lendrum AC. The staining of eosinophil polymorphs and enterochromaffin cells in histological sections. The Journal of Pathology and Bacteriology 1944, 56(3):441.
32. Teixeira-Carvalho A, Martins-Filho OA, Andrade ZA, Cunha-Mello JR, Wilson RA, Correa-Oliveira R. The study of T-cell activation in peripheral blood and spleen of hepatosplenic patients suggests an exchange of cells between these two compartments in advanced human Schitosomiasis mansoni infection. Scandinavian Journal Immunology 2002, 56:315-322.
33. Araujo MSS, Andrade RA, Vianna LR, Reis AB, Sathler-Avelar R, Teixeira-Carvalho A, Andrade MC, Mallo MN, Martins-Filho OA. Despite Leisvaccine and Leismune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 2008, 26:2211-24. 10.1016/j.vaccine.2008.02.044, 18395948.
34. Sheu BC, Kuo WH, Chen RJ, Huang KJ, Chow SN. Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. The Breast 2008, 17:604-610. 10.1016/j.breast.2008.06.001, 18656354.
35. Macchetti AH, Marana HRC, Silva JS, Andrade JM, Ribeiro-Silva A, Bighetti S. Tumor-infiltration CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics 2006, 61(3):203-208. 10.1590/S1807-59322006000300004, 16832552.
36. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, Seow HF. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunology Letters 2006, 102:229-236. 10.1016/j.imlet.2005.09.006, 16246429.
37. Forman J. T cells, the MHC, and function. Immunology 1984, 81:203-219.
38. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. Journal Experimental Medicine 1998, 188(12):2357-2368.
39. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nature Medicine 1998, 4(5):627-630. 10.1038/nm0598-627, 9585241.
40. Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. American Cancer Society 1999, 86(8):1537-1543.
41. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement, 1999. Archives Pathology & Laboratory Medicine 2000, 124:966-978.
42. Philibert JC, Snyder PW, Glickman N, Glickman LT, Waters J. Influence of host factors on survival in dogs with malignant mammary gland tumors. Journal Veterinary Internal Medicine 2003, 17:102-106.
43. Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, Cassali GD. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Veterinary and Comparative Oncology 2009, (193):1-6.
44. Withrow SJ, Mac Eween EG. Tumors of the mammary gland. Small Animal Clinical Oncology 2001, 455-77. W. B. Saunders Company, Philadelphia, Withrow SJ, Mac Eween EG, 3.
45. Marti{dotless}'n De Las Mulas J, Milla' NY, Dios R. A prospective analysis of immunohistochemically determined estrogen receptor α and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Veterinary Pathology 2005, 42:200-212. 10.1354/vp.42-2-200, 15753474.
46. Denkert C, Loibl S, Noske A, Roller M, MüLler BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 2010, 28(1):105-113. 10.1200/JCO.2009.23.7370, 19917869.
47. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 1998, 11(2):155-168.
48. Hellmén E, Bergström R, Holmberg L, Spangberg I-B, Hansson K, Lindgren A. Prognostic factors in canine mammary tumor: A multivariate study of 202 consecutive cases. Veterinary Pathology 1993, 30:20-27. 10.1177/030098589303000103, 8442324.